EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

BACKGROUND: Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. There is therefore a need to identify biomarkers that accurately predict the re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Med
Main Authors: Zheng, Qiufan, Hong, Shaodong, Huang, Yan, Zhao, Hongyun, Yang, Yunpeng, Hou, Xue, Zhao, Yuanyuan, Ma, Yuxiang, Zhou, Ting, Zhang, Yaxiong, Fang, Wenfeng, Zhang, Li
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7026329/
https://ncbi.nlm.nih.gov/pubmed/32067121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-020-0269-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados